{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:19:09Z","timestamp":1790720349751,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100030831","name":"Novartis Pharma K.K.","doi-asserted-by":"crossref","award":["CABC123DJP01T"],"award-info":[{"award-number":["CABC123DJP01T"]}],"id":[{"id":"10.13039\/100030831","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs is an innovative treatment for advanced well-differentiated neuroendocrine tumors (NETs). In Japan, PRRT with Lutetium-177 oxodotreotide (\n                      <jats:sup>177<\/jats:sup>\n                      Lu- oxodotreotide) was recently approved following Phase I and Phase I\/II clinical trials, which primarily assessed safety and response rates. However, its long-term efficacy and safety remain unclear. We conducted a record-based analysis of these trials to evaluate progression-free survival (PFS), overall survival (OS), and long-term safety.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We recruited Japanese patients from the Phase I and Phase I\/II clinical trials. Patients received four infusions of 7.4 GBq\n                      <jats:sup>177<\/jats:sup>\n                      Lu-oxodotreotide every 8 weeks. We reviewed the database records to assess OS, disease progression, and adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-one patients (median age, 57 years) were recruited. The primary tumor sites included the pancreas (n=11), small intestine (n=5), rectum (n=2), lungs (n=2), and stomach (n=1). Twenty (95.2%) patients had liver metastases, whereas 19 (90.5%) had grade 2 tumors. The median PFS period was 36.6 months; median OS period was not\u3000reached. Two (9.5%) patients achieved a complete response, 12 (57.1%) achieved a partial response, six (28.6%) had stable disease, and one (4.8%) had progressive disease. One patient had chronic myeloid leukemia 15 months post-PRRT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PRRT demonstrated sustained efficacy and safety in Japanese patients with NET.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12149-026-02169-1","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T10:27:54Z","timestamp":1770892074000},"page":"687-694","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-term efficacy and safety of peptide receptor radionuclide therapy in Japanese patients with unresectable neuroendocrine tumor: extension of the Japanese phase I and phase I\/II study"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9181-3722","authenticated-orcid":false,"given":"Noritoshi","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Akahoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"2169_CR1","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nrendo.2011.120","volume":"8","author":"G Rindi","year":"2011","unstructured":"Rindi G, Wiedenmann B. Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat Rev Endocrinol. 2011;8:54\u201364.","journal-title":"Nat Rev Endocrinol"},{"key":"2169_CR2","unstructured":"Klimstra D, Kl\u00f6ppel G, La Rosa S, Rindi G. Classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of tumours, 5th Edition. Digestive system tumours, vol. 1. IARC Press; 2019. p. 16\u20139."},{"key":"2169_CR3","unstructured":"Travis WD, Beasley M, Cree I, Papotti M, Rekhtman N. Lung neuroendocrine neoplasms. WHO Classification of Tumours: Thoracic Tumours. 2022:127-9."},{"key":"2169_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07581-y","volume":"20","author":"T Masui","year":"2020","unstructured":"Masui T, Ito T, Komoto I, Uemoto S, JNETS Project Study Group. Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study. BMC Cancer. 2020;20:1104.","journal-title":"BMC Cancer"},{"key":"2169_CR5","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, M\u00fcller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656\u201363.","journal-title":"J Clin Oncol"},{"key":"2169_CR6","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, Pavel M, \u0106wik\u0142a JB, Phan AT, Raderer M, Sedl\u00e1\u010dkov\u00e1 E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:224\u201333.","journal-title":"N Engl J Med"},{"key":"2169_CR7","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","volume":"387","author":"JC Yao","year":"2016","unstructured":"Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387:968\u201377.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"2169_CR8","first-page":"57","volume":"57","author":"EP Krenning","year":"1996","unstructured":"Krenning EP, Kooij PP, Pauwels S, Breeman WA, Postema PT, De Herder WW, et al. Somatostatin receptor: scintigraphy and radionuclide therapy. Digestion. 1996;57(Suppl 1):57\u201361.","journal-title":"Digestion"},{"key":"2169_CR9","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S0140-6736(05)78355-0","volume":"351","author":"A Otte","year":"1998","unstructured":"Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet. 1998;351:417\u20138.","journal-title":"Lancet"},{"key":"2169_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125\u201335.","journal-title":"N Engl J Med"},{"key":"2169_CR11","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/jhbp.1014","volume":"28","author":"N Kobayashi","year":"2021","unstructured":"Kobayashi N, Wild D, Kaul F, Shimamura T, Takano S, Takeda Y, et al. Retrospective study of peptide receptor radionuclide therapy for Japanese patients with advanced neuroendocrine tumors. J Hepatobiliary Pancreat Sci. 2021;28:727\u201339.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2169_CR12","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1007\/s12149-021-01674-9","volume":"35","author":"N Kobayashi","year":"2021","unstructured":"Kobayashi N, Takano S, Ito K, Sugiura M, Ogawa M, Takeda Y, et al. Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA0-Tyr3-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors. Ann Nucl Med. 2021;35:1332\u201341.","journal-title":"Ann Nucl Med"},{"key":"2169_CR13","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/jhbp.1101","volume":"29","author":"A Kudo","year":"2022","unstructured":"Kudo A, Tateishi U, Yoshimura R, Tsuchiya J, Yokoyama K, Takano S, et al. Safety and response after peptide receptor radionuclide therapy with 177 Lu-DOTATATE for neuroendocrine tumors in phase 1\/2 prospective Japanese trial. J Hepatobiliary Pancreat Sci. 2022;29:487\u201399.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2169_CR14","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel M, \u00d6berg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:844\u201360.","journal-title":"Ann Oncol"},{"key":"2169_CR15","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, et al. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403:2807\u201317.","journal-title":"Lancet"},{"key":"2169_CR16","unstructured":"Japan Neuroendocrine Society. Clinical practice guidelines for gastroenteropancreatic neoplasms (GEP-NENs). 2nd ed; 2025, 2019. Available from: https:\/\/jnets.umin.jp\/pdf\/guideline_cq9.pdf."},{"key":"2169_CR17","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","volume":"23","author":"T Brabander","year":"2017","unstructured":"Brabander T, van der Zwan WA, Teunissen JJ, Kam BL, Feelders RA, de Herder WW, et al. Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23:4617\u201324.","journal-title":"Clin Cancer Res"},{"key":"2169_CR18","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1007\/s00259-011-1902-1","volume":"38","author":"L Bodei","year":"2011","unstructured":"Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38:2125\u201335.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2169_CR19","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s10928-016-9470-4","volume":"43","author":"RP Shrestha","year":"2016","unstructured":"Shrestha RP, Horowitz J, Hollot CV, Germain MJ, Widness JA, Mock DM, et al. Models for the red blood cell lifespan. J Pharmacokinet Pharmacodyn. 2016;43:259\u201374.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2169_CR20","doi-asserted-by":"publisher","first-page":"452","DOI":"10.2967\/jnumed.117.189712","volume":"59","author":"H Bergsma","year":"2018","unstructured":"Bergsma H, van Lom K, Raaijmakers MH, Konijnenberg M, Kam BL, Teunissen JJ, et al. Persistent hematologic dysfunction after peptide receptor radionuclide therapy with 177Lu-DOTATATE: incidence, course, and predicting factors in patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2018;59:452\u20138.","journal-title":"J Nucl Med"},{"key":"2169_CR21","doi-asserted-by":"publisher","first-page":"L17","DOI":"10.1530\/ERC-15-0543","volume":"23","author":"B Brieau","year":"2016","unstructured":"Brieau B, Hentic O, Lebtahi R, Palazzo M, Ben Reguiga M, Rebours V, et al. High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy. Endocr Relat Cancer. 2016;23:L17-23.","journal-title":"Endocr Relat Cancer"},{"key":"2169_CR22","volume":"3","author":"S Kucukyurt","year":"2020","unstructured":"Kucukyurt S, Yagiz Ozogul YY, Ercaliskan A, Kabasakal L, Eskazan AE. Therapy-related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor. Cancer Rep. 2020;3:e1282.","journal-title":"Cancer Rep"},{"key":"2169_CR23","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s00259-010-1685-9","volume":"38","author":"E Vegt","year":"2011","unstructured":"Vegt E, Melis M, Eek A, de Visser M, Brom M, Oyen WJ, et al. Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice. Eur J Nucl Med Mol Imaging. 2011;38:623\u201332.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2169_CR24","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1007\/s00259-008-0778-1","volume":"35","author":"L Bodei","year":"2008","unstructured":"Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35:1847\u201356.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02169-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-026-02169-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02169-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T08:20:07Z","timestamp":1779956407000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-026-02169-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2169"],"URL":"https:\/\/doi.org\/10.1007\/s12149-026-02169-1","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"20 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Noritoshi Kobayashi received an honorarium from Novartis. K.K., Teijin Pharma, Teijin Healthcare, EA Pharma, Ono Pharmaceutical, Taiho Pharmaceutical, Yakult Honsha, Taiho Pharmaceutical, Yakult Honsha, MSD, and PD Radiopharma (successor to the radiopharmaceutical business of Fujifilm Toyama Chemical Co., Ltd.) and received support for research expenses from Novartis. K.K. The other authors declare no conflicts of interest. The funder had no role in the design of the study, collection, analyses, or interpretation of data, writing of the manuscript, or the decision to publish the results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}